| ▲ | 233mhz 34 minutes ago |
| > For once, this isn’t hyperbole. Am I missing something? From other sources: > Median overall survival: 13.2 months versus about 6.6 to 6.7 months with chemotherapy. |
|
| ▲ | scarmig 31 minutes ago | parent | next [-] |
| Doubling life expectancy on a form of cancer infamous as a death sentence. |
| |
| ▲ | shevy-java 22 minutes ago | parent [-] | | I don't see that as a breakthrough. Merely counting months does not do much - you'd have to count the quality of these months too. | | |
| ▲ | maxerickson 17 minutes ago | parent | next [-] | | An effect that large is a medical breakthrough regardless of your opinion of the treatment impact. | |
| ▲ | simtel20 17 minutes ago | parent | prev [-] | | Often pancreatic cancer is discovered only after it has spread. If this can treat it at that point it turns the disease from a death sentence to a lifeline until more research can come to fruition |
|
|
|
| ▲ | tedggh 27 minutes ago | parent | prev | next [-] |
| Everything is relative. A few more months of life with less pain and more energy to spend it with family surely is a breakthrough for many patients and for the doctors treating them. |
| |
| ▲ | shevy-java 21 minutes ago | parent [-] | | But where does it imply less pain? Plus, which pain exactly? Chemotherapy also leads to pain. Prolonging treatment can cause more pain then. I don't see that as a breakthrough. | | |
| ▲ | simtel20 13 minutes ago | parent | next [-] | | You're awfully negative about what a lot of people here see as a breakthrough. Can you be more descriptive about why you don't agree this constitutes a substantial difference other than saying you disagree and dismissing others' opinion? | |
| ▲ | msdz 13 minutes ago | parent | prev | next [-] | | I don’t think you have ever had to witness somebody undergoing chemotherapy. An alternative, if available is almost always better, and certainly less painful. | |
| ▲ | dgacmu 8 minutes ago | parent | prev [-] | | It sucks less than existing chemo: > Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group. That's a huge reduction in side effects bad enough to stop treatment. https://www.nejm.org/doi/full/10.1056/NEJMoa2605555? |
|
|
|
| ▲ | bonsai_spool 20 minutes ago | parent | prev [-] |
| That’s like a 100% increase over standard of care. Or a two-order-of-magnitude improvement. |
| |
| ▲ | csallen 15 minutes ago | parent [-] | | It's a 2× increase. Huge, but not two orders of magnitude, which would be a 100× increase. | | |
|